RE:RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker MiratiOctober 09, 2023 - Bristol Myers Squibb acquired KRAS inhibitor company Mirati for $5.8 billion.
https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Oncology-Portfolio-With-Acquisition-of-Mirati-Therapeutics/default.aspx
Krazati (adagrasib) was granted accelerated U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in combination with a PD-1 immune checkpoint inhibitor.
ONCY's reovirus (pelareorep) preferentially induces apoptosis in KRAS mutant colon cancer cells. Reovirus and irinotecan combination therapy is synergistic, p21 mediated, and represents a novel potential treatment for patients with CRC.
In October 2022 Sanjay Goel of the Albert Einstein College of Medicine reported on ONCY's pelareorep's effective synergy with PD-1 immune checkpoint inhibitors in the treatment of microsatellite stable colorectal cancers (mssCRCs).
https://einstein.elsevierpure.com/en/publications/oncolytic-reovirus-preferentially-induces-apoptosis-in-kras-mutan-2